The present invention provides: a novel method which makes it possible to improve or maintain a muscle amount or muscle strength; and a novel method which makes it possible to prevent obesity, reduce a body fat percentage, reduce a body fat amount, or reduce a fat-free mass. The proteoglycan to be used in the present invention is produced by a proteoglycan production method comprising a step for immersing a biological sample containing a proteoglycan in an aqueous solution of a surfactant and a step for collecting the solution obtained after the immersion.
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/57 - OiseauxSubstances provenant des oiseaux, p. ex. œufs, plumes, blanc d’œuf, jaune d’œuf ou endothelium corneum gigeriae galli
A61K 35/60 - Poissons, p. ex. hippocampesŒufs de poisson
A61K 35/618 - Mollusques, p. ex. mollusques d’eau douce, huîtres, palourdes, calmars, poulpes, seiches, escargots ou limaces
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
32 - Bières; boissons non alcoolisées
Produits et services
Collagen; collagen for industrial purposes; collagen used
for manufacture of nutritional supplements and cosmetics;
proteoglycan; proteoglycan for industrial purposes;
proteoglycan used for manufacture of nutritional supplements
and cosmetics. Pharmaceutical preparations; dietary supplements in the form
of powder, granular, tablet, solid and liquid; dietary
supplements for humans; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals; collagen-based pharmaceutical
preparations; collagen-based dietary supplements in the form
of powder, granular, tablet, solid and liquid;
collagen-based dietary supplements for humans;
collagen-based dietetic beverages adapted for medical
purposes; collagen-based dietetic foods adapted for medical
purposes; collagen-based beverages for babies;
collagen-based food for babies; collagen-based dietary
supplements for animals; proteoglycan-based pharmaceutical
preparations; proteoglycan-based dietary supplements in the
form of powder, granular, tablet, solid and liquid;
proteoglycan-based dietary supplements for humans;
proteoglycan-based dietetic beverages adapted for medical
purposes; proteoglycan-based dietetic foods adapted for
medical purposes; proteoglycan-based beverages for babies;
proteoglycan-based food for babies; proteoglycan-based
dietary supplements for animals; collagen and
proteoglycan-based pharmaceutical preparations; collagen and
proteoglycan-based dietary supplements in the form of
powder, granular, tablet, solid and liquid; collagen and
proteoglycan-based dietary supplements for humans; collagen
and proteoglycan-based dietetic beverages adapted for
medical purposes; collagen and proteoglycan-based dietetic
foods adapted for medical purposes; collagen and
proteoglycan-based beverages for babies; collagen and
proteoglycan-based food for babies; collagen and
proteoglycan-based dietary supplements for animals. Milk products; processed meat products; processed seafood
products; processed vegetables and fruits; fried tofu pieces
[abura-age]; freeze-dried tofu pieces [kohri-dofu]; jelly
made from devils' tongue root [konnyaku]; soya milk; tofu;
fermented soybeans [natto]; processed eggs; foodstuffs rich
in proteins, based on meat, fish, vegetables and dairy, for
human consumption; collagen-based milk products;
collagen-based processed meat products; collagen-based
processed seafood products; collagen-based processed
vegetables and fruits; collagen-based fried tofu pieces
[abura-age]; collagen-based freeze-dried tofu pieces
[kohri-dofu]; collagen-based jelly made from devils' tongue
root [konnyaku]; collagen-based soya milk; collagen-based
tofu; collagen-based fermented soybeans [natto];
collagen-based processed eggs; collagen-based foodstuffs
rich in proteins, based on meat, fish, vegetables and dairy,
for human consumption; proteoglycan-based milk products;
proteoglycan-based processed meat products;
proteoglycan-based processed seafood products;
proteoglycan-based processed vegetables and fruits;
proteoglycan-based fried tofu pieces [abura-age];
proteoglycan-based freeze-dried tofu pieces [kohri-dofu];
proteoglycan-based jelly made from devils' tongue root
[konnyaku]; proteoglycan-based soya milk; proteoglycan-based
tofu; proteoglycan-based fermented soybeans [natto];
proteoglycan-based processed eggs; proteoglycan-based
foodstuffs rich in proteins, based on meat, fish, vegetables
and dairy, for human consumption; collagen and
proteoglycan-based milk products; collagen and
proteoglycan-based processed meat products; collagen and
proteoglycan-based processed seafood products; collagen and
proteoglycan-based processed vegetables and fruits; collagen
and proteoglycan-based fried tofu pieces [abura-age];
collagen and proteoglycan-based freeze-dried tofu pieces
[kohri-dofu]; collagen and proteoglycan-based jelly made
from devils' tongue root [konnyaku]; collagen and
proteoglycan-based soya milk; collagen and
proteoglycan-based tofu; collagen and proteoglycan-based
fermented soybeans [natto]; collagen and proteoglycan-based
processed eggs; collagen and proteoglycan-based foodstuffs
rich in proteins, based on meat, fish, vegetables and dairy,
for human consumption. Carbonated drinks [refreshing beverages]; fruit juices;
vegetable juices [beverages]; whey beverages; collagen-based
carbonated drinks [refreshing beverages]; collagen-based
fruit juices; collagen-based vegetable juices [beverages];
collagen-based whey beverages; proteoglycan-based carbonated
drinks [refreshing beverages]; proteoglycan-based fruit
juices; proteoglycan-based vegetable juices [beverages];
proteoglycan-based whey beverages; collagen and
proteoglycan-based carbonated drinks [refreshing beverages];
collagen and proteoglycan-based fruit juices; collagen and
proteoglycan-based vegetable juices [beverages]; collagen
and proteoglycan-based whey beverages.
3.
COMPOSITION CONTAINING PLASMALOGEN FOR ENHANCING MEMORIZATION ABILITY
This is to provide a useful application of plasmalogen, which is not yet known.
This is to provide a useful application of plasmalogen, which is not yet known.
A composition contains plasmalogen for enhancing a verbal memorization ability and/or a visual memorization ability.
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
4.
Methods for producing compositions containing plasmalogen
Provided is a method for producing a composition containing plasmalogen derived from a plasmalogen-containing animal tissue, the method being without significantly decreasing an amount of plasmalogen derived the plasmalogen-containing animal tissue. A method for producing a composition containing plasmalogen derived from an animal tissue, the method comprising: (A) concentrating an alcohol extract of a plasmalogen-containing animal tissue, and (B) after diluting a concentrated product obtained by (A), allowing to stand under refrigeration.
A61K 35/616 - Échinodermes, p. ex. étoiles de mer, concombres de mer ou oursins
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
Provided is an oral intestinal tract cleansing agent which reduces the saltiness and bitterness thereof without relying on large amounts of sucralose, has a sulfate which exhibits a strong cleansing effect as an active ingredient thereof and does not incorporate polyethylene glycol therein. Additionally provided is an oral intestinal tract cleansing agent which reduces volume without requiring dilution. A pharmaceutical composition containing sodium sulfate, potassium sulfate and magnesium sulfate as active ingredients, the pharmaceutical composition being characterized by also containing thaumatin or a salt thereof as a sweetener. The pharmaceutical composition is preferably in the form of an aqueous solution, and the concentration of the thaumatin or salt thereof in the aqueous solution is preferably 0.2-10 mg/l, inclusive.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A61K 33/06 - Aluminium, calcium ou magnésiumLeurs composés
6.
PLASMALOGEN-CONTAINING COMPOSITION FOR INCREASING MEMORIZATION ABILITY
Provided is a useful but not publicly known application of plasmalogen. This plasmalogen-containing composition is for increasing a verbal memorization ability and/or a visual memorization ability.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 35/655 - Animaux aquatiques autres que ceux couverts par les groupes
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
7.
METHOD FOR PRODUCING PLASMALOGEN-CONTAINING COMPOSITION
Provided is a method for producing a composition containing plasmalogen derived from a plasmalogen-containing animal tissue, without significantly decreasing the amount of the plasmalogen derived from the animal tissue. A method for producing a composition containing plasmalogen derived from a plasmalogen-containing animal tissue, the method comprising: (A) concentrating an extract of the animal tissue with an alcohol to produce a concentrate; and (B) diluting the concentrate produced in (A) and then allowing the concentrate to leave under refrigerated conditions.
A61K 31/683 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 35/616 - Échinodermes, p. ex. étoiles de mer, concombres de mer ou oursins
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C11B 11/00 - Obtention ou raffinage d'autres matières grasses, p. ex. lanoline ou cires
8.
PHARMACEUTICAL COMPOSITION, METHOD FOR STABILISNG PHARMACEUTICAL COMPOSITION, AND METHOD FOR EVALUATING STORAGE STABILITY OF PHARMACEUTICAL COMPOSITION
Provided is a pharmaceutical composition that exhibits superior storage stability even if mixed with a high concentration of L-menthol. The pharmaceutical composition comprises a component (A), a component (B), a component (C), a component (D) and a component (E) as detailed hereinafter, and has a cloud point of 30–75°C. Component (A): L-menthol. Component (B): At least one substance selected from the group consisting of medium-chain fatty-acid triglycerides, medium-chain fatty acids and salts of medium-chain fatty acids. Component (C): A nonionic surfacant having a HLB of at least 10. Component (D): A polyhydric alcohol comprising at least three hydroxl groups within a molecule; and/or a poly(oxyalkylene) glycol. Component (E): Water.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
9.
AGENT FOR THE PREVENTION OR TREATMENT OF HEPATIC FIBROSIS DISEASE
Provided is an agent for the prevention or treatment of a hepatic fibrosis disease in which there are used bone-marrow-derived stem cells that continuously demonstrate a liver-regenerating and fiber-degrading effect. An agent for the prevention or treatment of a hepatic fibrosis disease, the agent being characterized by including, as an active component, bone-marrow-derived stem cells that have ischemic tolerance and that accumulate in the liver. The hepatic fibrosis disease preferably is cirrhosis of the liver. Also provided is a method for producing such an agent for the prevention or treatment of a hepatic fibrosis disease.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
[Problem]To provide a novel technique, which is more effective in the treatment of portal vein thrombosis. [Solution] This portal vein thrombosis therapeutic agent contains an antithrombin III as an active ingredient, is administered to patients with portal vein thrombosis in an antithrombin III-administered dosage of 1000-3600 IU/day for 5 days, and is re-administered at an interval of 0-4 days in the same dosage and period.
Provided is a drug that can effectively inhibit histone-mediated cytotoxicity. The drug for inhibiting histone-mediated cytotoxicity is characterized by having antithrombin III as an active ingredient. The antithrombin III is preferably β-antithrombin III.
In order to improve the resection efficiency, operability, and safety of endoscopic mucosal resection operations, a method has conventionally been employed wherein a cushioning agent such as physiological saline is injected into the layer below the area designated for resection, causing the lesion to lift and protrude (hereafter simply referred to as "protrusion"), after which the lesion is removed. It is difficult to accurately remove the intended area using conventional cushioning agents because applying pressure to the protrusion tends to cause deformation thereof, the degree of protrusion is low, and the cushioning agent diffuses immediately after injection into the peripheral tissue, thereby causing the protrusion to disappear. The present invention solves these problems by employing a polysaccharide having a pseudoplastic viscosity such as xantham gum, carrageenan, gellan gum, guar gum, locust bean gum, sacran, or the like as a cushioning agent.
This is to provide a novel medicine and a food and a drink composition for treating aesthenopia excellent in improved effect of aesthenopia.
The composition for the treatment of aesthenopia comprises chondroitin sulfate or a salt thereof.
A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits
Provided is a novel fusion protein, which can specifically suppress an autoantibody and can effectively prevent or treat an autoantibody autoimmune disease, and the expression level of which is industrially sufficient. A fusion protein, in which a protein (X) containing a site recognized by an autoantibody causing an autoantibody autoimmune disease is connected to a protein (A) containing a fragment exhibiting the antibody-dependent cellular cytotoxic activity of an antibody heavy chain constant domain through a linker peptide (L) comprising one or more amino acids, and which is characterized in that the protein (X), the linker peptide (L), and the protein (A) are connected in this order from the N-terminus to the C-terminus through a peptide bond.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
Disclosed are a novel drug and a food or drink composition for the treatment of aesthenopia which are effective in ameliorating aesthenopia. The disclosed composition for the treatment of aesthenopia is formed by a mixture with condroitin sulfate or a salt thereof.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
Disclosed is a novel prophylactic or therapeutic agent for inflammatory diseases. Specifically disclosed is a prophylactic or therapeutic agent for inflammatory bowel diseases or autoimmune peripheral neuropathy, which contains, as an active ingredient, a compound represented by general formula (I) or general formula (II), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. (In general formula (I), n represents an integer of 1-10; X1 represents -CHY-C(CH3)2Z (wherein Y and Z each independently represents -H or -OH, or alternatively Y and Z combine together to form a single bond); R1 represents a hydrogen atom or a residue of a pharmaceutically acceptable ester; and R2s may be the same or different and each represents a hydrogen atom or a protecting group of a hydroxyl group.) (In general formula (II), X2 represents -CHY-C(CH3)2Z (wherein Y and Z each independently represents -H or -OH, or alternatively Y and Z combine together to form a single bond); R4s may be the same or different and each represents a hydrogen atom or a protecting group of a hydroxyl group; and R3 represents a six-membered ring group or a fused ring group thereof.)
C07D 491/052 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à six chaînons
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
17.
AGENT FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE
Disclosed is an agent for the prevention or treatment of inflammatory bowel disease, which comprises as the active ingredient a polypeptide that has a sequence being at least 70% identical to that of human paraoxonase and that has at least one activity selected from the group consisting of lactonase activity, paraoxonase activity, allyl esterase activity, and active oxygen-consuming activity.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
Disclosed is an autoantibody production inhibitor which can inhibit an autoantibody specifically and can prevent or treat autoantibody autoimmune diseases effectively. The autoantibody production inhibitor is characterized by comprising, as an active ingredient, a fusion protein composed of a protein (X) and a protein (A), wherein the protein (X) comprises a segment which can be recognized by an autoantibody that causes autoantibody autoimmune diseases and the protein (A) comprises a fragment of an antibody heavy-chain constant-region which has an antibody-dependent cytotoxic activity.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4
A61P 5/16 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4 pour réduire, bloquer ou contrarier l'activité des hormones thyroïdiennes
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
[PROBLEMS] The object is to provide a prophylactic/therapeutic agent for articular rheumatism, which can prevent and alleviate the progression of a condition of articular rheumatism at any stage between the initial stage and an advanced stage of articular rheumatism without causing any adverse side effect. [MEANS FOR SOLVING PROBLEMS] Apolipoprotein A-II is one of the primary constituent proteins of high-density lipoproteins (HDL). It is found that a pharmaceutical composition for parenteral administration which comprises apolipoprotein A-II as an active ingredient can be used as a safe and effective prophylactic/therapeutic agent for articular rheumatism.
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
20.
REMEDY FOR ACUTE HEPATITIS OR PREVENTIVE/REMEDY FOR FULMINANT HEPATITIS
[PROBLEMS] In the case where acute hepatitis progresses to fulminant hepatitis, a large amount of hepatocytes are rapidly broken and, in its turn, the prognosis is seriously worsened. Thus, it is meaningful to predict the progress of acute hepatitis into fulminant hepatitis at the early stage and quickly start an appropriate treatment therefor. Although the prediction of fulminant hepatitis becomes possible owing to the recent advances in test methods and diagnostic techniques, there has been no appropriate preventive/remedy for fulminant hepatitis. Under these circumstances, it is intended to provide a remedy for acute hepatitis or a preventive/remedy for fulminant hepatitis with little side effect. [MEANS FOR SOLVING PROBLEMS] A medicinal composition for solving the above problem which contains apolipoprotein A-II.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
An emulsion comprising L-Menthol, a fat or oil and a surfactant wherein oil particles have an average diameter of 100 nm or less inhibits a content reduction attributed to, for example, evaporation of L-menthol, enhances a light transmission through liquid and is stable despite long-term storage. Thus, the emulsion can be appropriately used in the temporary inhibition of contraction of gastrointestinal tract for, for example, observation of gastrointestinal tract by an endoscope. This emulsion can be obtained by heating an oil-in-water type emulsion comprising L-menthol, a fat or oil and a surfactant at 60° C. or higher.
